25.05.2022 11:30

The Zacks Analyst Blog Highlights Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group

Folgen
Werbung
For Immediate ReleaseChicago, IL – May 25, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bank of America Corp. BAC, Novo Nordisk A/S NVO, Novartis AG NVS, Analog Devices, Inc. ADI and Sony Group Corp. SONY.Here are highlights from Tuesday’s Analyst Blog:Top Analyst Reports for B of A, Novo Nordisk and NovartisThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corp., Novo Nordisk A/S, and Novartis AG. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Bank of America shares have declined -14.6% over the past year against the Zacks Banks - Major Regional industry's decline of -16.6%. However, the company's first-quarter 2022 results benefited substantially from loan growth and higher rates.The Zacks analyst believes that the opening of financial centers, enhancement in digital capabilities and cost-saving efforts will likely keep aiding profits. Supported by robust loan growth and the investment banking (IB) pipeline, the company's top line is expected to keep improving.Bank of America is expected to keep enhancing shareholder value through impressive capital deployments. However, despite the expected rate hikes in 2022, relatively low rates might hurt margins and interest income for some time in the near term. The volatile nature of the trading business is concerning as it might hamper fee income growth.(You can read the full research report on Bank of America here >>>)Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+34.2% vs. +20.0%) on the back of one of the broadest diabetes portfolios in the industry. Ozempic, Rybelsus, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of these existing drugs is expected to further boost sales.However, lower realized prices in the Unites States, loss of exclusivity for products and stiff competition are affecting sales. Sales are also being negatively impacted by the COVID-19 pandemic. Also, the supply challenges for Wegovy have hurt the stock. The patent expiry on some of the products in Novo Nordisk's portfolio is concerning too.(You can read the full research report on Novo Nordisk here >>>)Novartis shares have gained +3.7% in the year to date period against the Zacks Large Cap Pharmaceuticals industry's gain of +5.1%. Novartis' performance in the first quarter, in fact, was good as the lagging Sandoz business returned to growth and cardiovascular drug Entresto maintained its stellar performance.The Zacks analyst believes that drugs like Cosentyx, Entresto, Kesimpta, gene therapy Zolgensma, Kisqali and Leqvio should continue to fuel growth and offset the impact of generic competition. The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent, and the label expansion of key drugs should also aid performance. However, generic competition for key drugs and pipeline setbacks poses concerns.(You can read the full research report on Novartis here >>>)Other noteworthy reports we are featuring today include Analog Devices, Inc., and Sony Group Corp.Why Haven't You Looked at Zacks' Top Stocks?Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.See Stocks Free >>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.comhttps://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bank of America Corporation (BAC): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Analog Devices, Inc. (ADI): Free Stock Analysis Report Novo Nordisk AS (NVO): Free Stock Analysis Report Sony Corporation (SONY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Weiter zum vollständigen Artikel bei "Zacks"
Ausgewählte Hebelprodukte auf Analog Devices Inc.
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Analog Devices Inc.
Long
Short
Hebel wählen:
5x
10x
Name
Hebel
KO
Emittent
Quelle: Zacks

Nachrichten zu Novartis AG

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Novartis AG

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
22.06.2022Novartis NeutralUBS AG
22.06.2022Novartis UnderweightJP Morgan Chase & Co.
22.06.2022Novartis SellDeutsche Bank AG
27.05.2022Novartis BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
05.05.2022Novartis BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
27.05.2022Novartis BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
05.05.2022Novartis BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
28.04.2022Novartis Conviction Buy ListGoldman Sachs Group Inc.
26.04.2022Novartis BuyJefferies & Company Inc.
19.04.2022Novartis BuyJefferies & Company Inc.
22.06.2022Novartis NeutralUBS AG
27.04.2022Novartis NeutralCredit Suisse Group
27.04.2022Novartis NeutralUBS AG
26.04.2022Novartis NeutralUBS AG
08.04.2022Novartis NeutralUBS AG
22.06.2022Novartis UnderweightJP Morgan Chase & Co.
22.06.2022Novartis SellDeutsche Bank AG
27.04.2022Novartis UnderweightJP Morgan Chase & Co.
27.04.2022Novartis SellDeutsche Bank AG
26.04.2022Novartis UnderweightJP Morgan Chase & Co.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novartis AG nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen

Jetzt noch kostenlos anmelden!

Inflation, Leitzinserhöhung und Bärenmärkte - aber wie sieht es eigentlich am Immobilienmarkt aus? Wenn auch Sie sich den Traum einer eigenen Immobilie erfüllen möchten, erfahren Sie im Online-Seminar am Montag um 18 Uhr wie Sie Schritt für Schritt das passende Objekt finden und welche Finanzierungsmöglichkeiten es gibt!

Werbung
Werbung
Werbung
Neue Funktionen als Erstes nutzen
Sie nutzen finanzen.net regelmäßig? Dann nutzen Sie jetzt neue Funktionen als Erstes!
Hier informieren!
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

Ukraine-Krieg im Ticker: DAX schließt Freitagshandel über 13.100 Punkten -- US-Börsen legen markant zu -- Zalando kassiert Jahresprognose -- GAZPROM, TUI, Porsche-IPO, Amazon, Deutsche Bank im Fokus

IMMOFINANZ will Objekte in Milliardenwert verkaufen. Streik des Kabinen-Personals führt zu Flug-Ausfällen bei Ryanair. Henkel macht laut CEO Knobel Fortschritte beim Rückzug aus Russland. RWE plant Wasserstoff-Produktionsanlage in Rostock. Stellantis steigt bei Lithium-Unternehmen Vulcan Energy ein. Stifel startet Vonovia mit "Hold". Zurich trennt sich von deutschen Lebensversicherungs-Altbeständen.

Umfrage

Sollte das 9-Euro-Ticket über den August hinaus verlängert werden?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln